Piramal Pharma Solutions investing $80M to expand Lexington manufacturing, create 45 jobs
Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million investment creating 45 new full-time jobs in the area.
Piramal Pharma Solutions draws $80 mn expansion plan for injectables facility in US
Piramal Pharma Solutions (PPS), the global contract manufacturing division of Piramal Pharma Ltd, is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky. Piramal's global Contract Development and Manufacturing ...
Piramal Pharma Solutions Plans $80M Expansion for Kentucky Facility
As the efficiency and efficacy of injectable treatment options improve, more patients are expected to benefit from advanced therapies.
Piramal Pharma Announces Rs 670-Crore Expansion Plan For Sterile Injectables Plant In US
The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new lab, and state‐of‐the‐art machinery.
Piramal Pharma to invest $80 million in expanding Kentucky's sterile injectables facility
The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising demand, said the company.
Piramal Pharma Solutions Announces $80M Expansion Plan for Sterile Injectables Facility in Lexington, Kentucky
Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma
Piramal Pharma to invest $80 million in Kentucky facility expansion
Piramal Pharma Solutions invests $80 million in Lexington facility expansion to meet growing demand in injectables market.
Piramal Pharma Ahmedabad facility gets EIR from USFDA
Piramal Pharma’s stock price rose 2% in the opening trading on September 30 after the business received an Establishment Inspection Report (EIR) for its production facility in Ahmedabad, India. The USFDA examined the plant in July 2024 and issued a No Action Indicated (NAI) classification based on Zero Form – 483 observations.
USFDA issues EIR for Piramal Pharma Ahmedabad facility
Mumbai: Piramal Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its manufacturing facility in Ahmedabad, India. This follows
Piramal Pharma to invest $80M to expand its Lexington, Kentucky facility
Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma has unveiled an $80M investment plan to expand its Lexington, Kentucky facility.
US Firms Reaching Out as Biosecure Act Closes in, Piramal Says
US drugmakers have begun reaching out to explore contract manufacturing possibilities to Piramal Pharma Ltd. as they gear up ...
Piramal Pharma shares gain 2% after EIR from USFDA for Ahmedabad facility
In July 2024, the USFDA inspected the said facility with Zero Form - 483 observations and No Action Indicated (NAI) ...
Meet Nandini Piramal, Isha Ambani's sister-in-law and chairman of Piramal Pharma, her worth is
Nandini Piramal has earned an MBA from Stanford University Graduate School of Business, California. She also holds a Bachelor ...